In an unusual agreement, imaging giant Siemens Medical Systems has joined forces with Cardiovascular Consultants (CC), a large medical group specializing in cardiovascular disease, to develop imaging protocols for three modalities the new partners
In an unusual agreement, imaging giant Siemens Medical Systems has joined forces with Cardiovascular Consultants (CC), a large medical group specializing in cardiovascular disease, to develop imaging protocols for three modalities the new partners believe hold major potential in identification and treatment of heart disease. Under the five-year pact, CC and Siemens will collaborate on protocols for PET, MRI, and CT.
What makes the alliance unusual is the incorporation of three high-profile, noninvasive modalities in an office practice rather than a university or large hospital setting. In essence, CC joins the ranks of other Siemens luminary sites: the Cleveland Clinic Foundation, the Mayo Clinic, Johns Hopkins University, New York University, Cedars-Sinai Medical Center, Stanford University, and Northwestern University.
“What differentiates this from other Siemens alliances is the setting,” said Robert Dewey, director of Siemens’ cardiology program. “Cardiovascular Consultants represents the physician office practice setting rather than the more traditional large hospital, where such alliances often are structured. It provides an opportunity to evaluate the roles of traditional and emerging imaging modalities in an environment that reflects the priorities of a large segment of our customer base.”
According to CC, each modality holds promise for various aspects of cardiac imaging: PET for perfusion imaging, MRI for vascular imaging and the detection of small infarcts, and CT for identifying atherosclerosis. Other systems eventually may be incorporated as well. The systems will be based at CC’s research center in its Mid-America Heart Institute, said Dr. Timothy Bateman, director of cardiac and vascular noninvasive imaging for the institute.
“There will be one of each system, and they will all be equipped and dedicated for cardiac and vascular applications,” Bateman said.
Cardiovascular Consultants, based in Kansas City, MO, purchased the imaging equipment from Siemens “at a favorable price,” according to Siemens. Placement of the systems in the research facility, which will serve as a demonstration site, will enable the group to conduct clinical trials, collect new data, and analyze patient data collected over the past 20 years:
Software used to drive the modalities will be developed cooperatively by Siemens and CC, and Siemens researchers will work on-site. Ultimately, the effort is expected to result in partnerships with radiopharmaceutical, software, and technology companies, Bateman said. Those relationships could ultimately short millions of dollars in additional research funding to CC and the institute.
“We are conducting the kinds of research that should be fundable by governmental agencies, such as the National Institutes of Health,” Bateman said. “We will certainly compete for that.”
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.